Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Rusch (2009)
The Mars trial: resolution of the surgical controversies in mesothelioma?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 4 10
L. Lang-Lazdunski, A. Billé, E. Belcher, P. Cane, D. Landau, J. Steele, H. Taylor, J. Spicer (2011)
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 6
R. Flores, H. Pass, V. Seshan, J. Dycoco, M. Zakowski, M. Carbone, M. Bains, V. Rusch (2008)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.The Journal of thoracic and cardiovascular surgery, 135 3
W. Weder, R. Stahel, P. Baas, U. Dafni, M. Perrot, B. McCaughan, T. Nakano, H. Pass, B. Robinson, V. Rusch, D. Sugarbaker, N. Zandwijk (2011)
The MARS feasibility trial: conclusions not supported by data.The Lancet. Oncology, 12 12
T. Treasure, L. Lang-Lazdunski, D. Waller, J. Bliss, Carol Tan, J. Entwisle, M. Snee, M. O'Brien, G. Thomas, S. Senan, K. O'Byrne, L. Kilburn, J. Spicer, D. Landau, J. Edwards, G. Coombes, L. Darlison, J. Peto (2011)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet. Oncology, 12
R. Flores (2009)
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.Seminars in thoracic and cardiovascular surgery, 21 2
EDIToRIAL Is it Time to Consider Pleurectomy and Decortication as the Only Surgical Treatment for Malignant Pleural Mesothelioma? Michael J. Weyant, MD adical extrapleural pneumonectomy (EPP), and pleurectomy and decortication (P/D) Rhave emerged as the two main surgical treatments of malignant pleural mesothelioma (MPM). Until recently, EPP has been considered the gold standard operation with P/D being performed if the patient’s physical status or preference dictated it. The operative mortality of EPP is reported to be as high as 18% in some series that has generated interest in studying the P/D procedure more intensively because of lesser complications and pos- sibly better survival rates reported. Flores et al. reported on a series of 663 patients who underwent either EPP or P/D as part of their treatment for MPM . This is the largest series to date examining the outcomes of P/D as a modality of treatment for MPM. Their results demonstrate that there may be circumstances, such as in stage-I disease where an R0 resec- tion is attained, in which P/D is a superior, less-morbid therapy. Likewise there may be a benefit to EPP in patients who have more extensive disease (stage II). This data suggests that the main
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Apr 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.